{"document_text": "Neuromuscular junction - wikipedia <H1> Neuromuscular junction </H1> Jump to : navigation , search At the neuromuscular junction , the nerve fiber is able to transmit a signal to the muscle fiber by releasing ACh ( and other substances ) , causing muscle contraction . Muscles will contract or relax when they receive signals from the nervous system . The neuromuscular junction is the site of the signal exchange . The steps of this process in vertebrates occur as follows : ( 1 ) The action potential reaches the axon terminal . ( 2 ) Voltage - dependent calcium gates open , allowing calcium to enter the axon terminal . ( 3 ) Neurotransmitter vesicles fuse with the presynaptic membrane and ACh is released into the synaptic cleft via exocytosis. ( 4 ) ACh binds to postsynaptic receptors on the sarcolemma. ( 5 ) This binding causes ion channels to open and allows sodium ions to flow across the membrane into the muscle cell . ( 6 ) The flow of sodium ions across the membrane into the muscle cell generates an action potential which travels to the myofibril and results in muscle contraction. Labels : A : Motor Neuron AxonB : Axon TerminalC . Synaptic CleftD . Muscle CellE . Part of a Myofibril <Table> <Tr> <Th_colspan=\"2\"> Neuromuscular junctions </Th> </Tr> <Tr> <Td_colspan=\"2\"> Electron micrograph showing a cross section through the neuromuscular junction . T is the axon terminal , M is the muscle fiber . The arrow shows junctional folds with basal lamina . Active zones are visible on the tips between the folds . Scale is 0.3 \u03bcm . Source : NIMH </Td> </Tr> <Tr> <Td_colspan=\"2\"> Detailed view of a neuromuscular junction : <Ol> <Li> Presynaptic terminal </Li> <Li> Sarcolemma </Li> <Li> Synaptic vesicle </Li> <Li> Nicotinic acetylcholine receptor </Li> <Li> Mitochondrion </Li> </Ol> </Td> </Tr> <Tr> <Th_colspan=\"2\"> Details </Th> </Tr> <Tr> <Th_colspan=\"2\"> Identifiers </Th> </Tr> <Tr> <Th> Latin </Th> <Td> synapssis neuromuscularis ; junctio neuromuscularis </Td> </Tr> <Tr> <Th> MeSH </Th> <Td> D009469 </Td> </Tr> <Tr> <Th> TH </Th> <Td> H2. 00.06. 1.02001 </Td> </Tr> <Tr> <Th> FMA </Th> <Td> 61803 </Td> </Tr> <Tr> <Td_colspan=\"2\"> Anatomical terminology ( edit on Wikidata ) </Td> </Tr> </Table> <P> A neuromuscular junction ( or myoneural junction ) is a chemical synapse formed by the contact between a motor neuron and a muscle fiber . It is at the neuromuscular junction that a motor neuron is able to transmit a signal to the muscle fiber , causing muscle contraction . </P> <P> Muscles require innervation to function -- and even just to maintain muscle tone , avoiding atrophy . Synaptic transmission at the neuromuscular junction begins when an action potential reaches the presynaptic terminal of a motor neuron , which activates voltage - dependent calcium channels to allow calcium ions to enter the neuron . Calcium ions bind to sensor proteins ( synaptotagmin ) on synaptic vesicles , triggering vesicle fusion with the cell membrane and subsequent neurotransmitter release from the motor neuron into the synaptic cleft . In vertebrates , motor neurons release acetylcholine ( ACh ) , a small molecule neurotransmitter , which diffuses across the synaptic cleft and binds to nicotinic acetylcholine receptors ( nAChRs ) on the cell membrane of the muscle fiber , also known as the sarcolemma . nAChRs are ionotropic receptors , meaning they serve as ligand - gated ion channels . The binding of ACh to the receptor can depolarize the muscle fiber , causing a cascade that eventually results in muscle contraction . </P> <P> Neuromuscular junction diseases can be of genetic and autoimmune origin . Genetic disorders , such as Duchenne muscular dystrophy , can arise from mutated structural proteins that comprise the neuromuscular junction , whereas autoimmune diseases , such as myasthenia gravis , occur when antibodies are produced against nicotinic acetylcholine receptors on the sarcolemma . </P> <P> </P> <H2> Contents </H2> ( hide ) <Ul> <Li> 1 Structure and function <Ul> <Li> 1.1 Mechanism of action </Li> <Li> 1.2 Acetylcholine receptors </Li> </Ul> </Li> <Li> 2 Development </Li> <Li> 3 Research methods </Li> <Li> 4 Toxins that affect the neuromuscular junction <Ul> <Li> 4.1 Nerve gases </Li> <Li> 4.2 Botulinum toxin </Li> <Li> 4.3 Tetanus toxin </Li> <Li> 4.4 Latrotoxin </Li> <Li> 4.5 Snake venom </Li> </Ul> </Li> <Li> 5 Diseases <Ul> <Li> 5.1 Autoimmune <Ul> <Li> 5.1. 1 Myasthenia gravis <Ul> <Li> 5.1. 1.1 Neonatal MG </Li> </Ul> </Li> <Li> 5.1. 2 Lambert - Eaton myasthenic syndrome </Li> <Li> 5.1. 3 Neuromyotonia </Li> </Ul> </Li> <Li> 5.2 Genetic <Ul> <Li> 5.2. 1 Congenital myasthenic syndromes </Li> <Li> 5.2. 2 Bulbospinal muscular atrophy </Li> <Li> 5.2. 3 Duchenne muscular dystrophy </Li> </Ul> </Li> </Ul> </Li> <Li> 6 See also </Li> <Li> 7 External links </Li> <Li> 8 Further reading </Li> <Li> 9 References </Li> </Ul> <P> </P> <H2> Structure and function ( edit ) </H2> motor endplate <P> The neuromuscular junction differs from chemical synapses between neurons . Presynaptic motor axons stop 30 nanometers from the sarcolemma , the cell membrane of a muscle cell . This 30 - nanometer space forms the synaptic cleft through which signalling molecules are released . The sarcolemma has invaginations called postjunctional folds , which increase the surface area of the membrane exposed to the synaptic cleft . These postjunctional folds form what is referred to as the motor endplate , which possess nicotinic acetylcholine receptors ( nAChRs ) at a density of 10,000 receptors / micrometer in skeletal muscle . The presynaptic axons form bulges called terminal boutons ( or presynaptic terminals ) that project into the postjunctional folds of the sarcolemma . The presynaptic terminals have active zones that contain vesicles , also called quanta , full of acetylcholine molecules . These vesicles can fuse with the presynaptic membrane and release ACh molecules into the synaptic cleft via exocytosis after depolarization . AChRs are localized opposite the presynaptic terminals by protein scaffolds at the postjunctional folds of the sarcolemma . Dystrophin , a structural protein , connects the sarcomere , sarcolemma , and extracellular matrix components . Rapsyn is another protein that docks AChRs and structural proteins to the cytoskeleton . Also present is the receptor tyrosine kinase protein MuSK , a signaling protein involved in the development of the neuromuscular junction , which is also held in place by rapsyn . </P> <H3> Mechanism of action ( edit ) </H3> <P> The neuromuscular junction is where a neuron activates a muscle to contract . Upon the arrival of an action potential at the presynaptic neuron terminal , voltage - dependent calcium channels open and Ca ions flow from the extracellular fluid into the presynaptic neuron 's cytosol . This influx of Ca causes neurotransmitter - containing vesicles to dock and fuse to the presynaptic neuron 's cell membrane through SNARE proteins . Fusion of the vesicular membrane with the presynaptic cell membrane results in the emptying of the vesicle 's contents ( acetylcholine ) into the synaptic cleft , a process known as exocytosis . Acetylcholine diffuses into the synaptic cleft and can bind to the nicotinic acetylcholine receptors on the motor endplate , causing calcium ions to flow into the muscle cell , initiating a sequence of steps that finally produce muscle contraction . </P> <H3> Acetylcholine receptors ( edit ) </H3> <Ol> <Li> Ion channel linked receptor </Li> <Li> Ions </Li> <Li> Ligand ( such as acetylcholine ) </Li> </Ol> When ligands bind to the receptor , the ion channel portion of the receptor opens , allowing ions to pass across the cell membrane . <P> Acetylcholine is a neurotransmitter synthesized from dietary choline and acetyl - CoA ( ACoA ) , and is involved in the stimulation of muscle tissue in vertebrates as well as in some invertebrate animals . In vertebrate animals , the acetylcholine receptor subtype that is found at the neuromuscular junction of skeletal muscles is the nicotinic acetylcholine receptor ( nAChR ) , which is a ligand - gated ion channel . Each subunit of this receptor has a characteristic `` cys - loop '' , which is composed of a cysteine residue followed by 13 amino acid residues and another cysteine residue . The two cysteine residues form a disulfide linkage which results in the `` cys - loop '' receptor that is capable of binding acetylcholine and other ligands . These cys - loop receptors are found only in eukaryotes , but prokaryotes possess ACh receptors with similar properties . Not all species use a cholinergic neuromuscular junction ; e.g. crayfish and fruit flies have a glutamatergic neuromuscular junction . </P> <P> AChRs at the skeletal neuromuscular junction form heteropentamers composed of two \u03b1 , one \u03b2 , one \u025b , and one \u03b4 subunits . When a single ACh ligand binds to one of the \u03b1 subunits of the ACh receptor it induces a conformational change at the interface with the second AChR \u03b1 subunit . This conformational change results in the increased affinity of the second \u03b1 subunit for a second ACh ligand . AChRs therefore exhibit a sigmoidal dissociation curve due to this cooperative binding . The presence of the inactive , intermediate receptor structure with a single - bound ligand keeps ACh in the synapse that might otherwise be lost by cholinesterase hydrolysis or diffusion . The persistence of these ACh ligands in the synapse can cause a prolonged post-synaptic response . </P> <H2> Development ( edit ) </H2> <P> The development of the neuromuscular junction requires signaling from both the motor neuron 's terminal and the muscle cell 's central region , During development , muscle cells produce acetylcholine receptors ( AChRs ) and express them in the central regions in a process called prepatterning . Agrin , a heparin proteoglycan , and MuSK kinase are thought to help stabilize the accumulation of AChR in the central regions of the myocyte . MuSK is a receptor tyrosine kinase -- meaning that it induces cellular signaling by binding phosphate molecules to self regions like tyrosines , and to other targets in the cytoplasm . Upon activation by its ligand agrin , MuSK signals via two proteins called `` Dok - 7 '' and `` rapsyn '' , to induce `` clustering '' of acetylcholine receptors . ACh release by developing motor neurons produces postsynaptic potentials in the muscle cell that positively reinforces the localization and stabilization of the developing neuromuscular junction . </P> <P> These findings were demonstrated in part by mouse `` knockout '' studies . In mice which are deficient for either agrin or MuSK , the neuromuscular junction does not form . Further , mice deficient in Dok - 7 did not form either acetylcholine receptor clusters or neuromuscular synapses . </P> <P> The development of neuromuscular junctions is mostly studied in model organisms , such as rodents . In addition , in 2015 an all - human neuromuscular junction has been created in vitro using human embryonic stem cells and somatic muscle stem cells . In this model presynaptic motor neurons are activated by optogenetics and in response synaptically connected muscle fibers twitch upon light stimulation . </P> <H2> Research methods ( edit ) </H2> <P> Jos\u00e9 del Castillo and Bernard Katz used ionophoresis to determine the location and density of nicotinic acetylcholine receptors ( nAChRs ) at the neuromuscular junction . With this technique , a microelectrode was placed inside the motor endplate of the muscle fiber , and a micropipette filled with acetylcholine ( ACh ) is placed directly in front of the endplate in the synaptic cleft . A positive voltage was applied to the tip of the micropipette , which caused a burst of positively charged ACh molecules to be released from the pipette . These ligands flowed into the space representing the synaptic cleft and bound to AChRs . The intracellular microelectrode monitored the amplitude of the depolarization of the motor endplate in response to ACh binding to nicotinic ( ionotropic ) receptors . Katz and del Castillo showed that the amplitude of the depolarization ( excitatory postsynaptic potential ) depended on the proximity of the micropipette releasing the ACh ions to the endplate . The farther the micropipette was from the motor endplate , the smaller the depolarization was in the muscle fiber . This allowed the researchers to determine that the nicotinic receptors were localized to the motor endplate in high density . </P> <P> Toxins are also used to determine the location of acetylcholine receptors at the neuromuscular junction . \u03b1 - Bungarotoxin is a toxin found in the snake species Bungarus multicinctus that acts as an ACh antagonist and binds to AChRs irreversibly . By coupling assayable enzymes such as horseradish peroxidase ( HRP ) or fluorescent proteins such as green fluorescent protein ( GFP ) to the \u03b1 - bungarotoxin , AChRs can be visualized and quantified . </P> <H2> Toxins that affect the neuromuscular junction ( edit ) </H2> <H3> Nerve gases ( edit ) </H3> <P> Nerve gases and liquor damage this area . </P> <H3> Botulinum toxin ( edit ) </H3> <P> Botulinum toxin ( aka botulinum neurotoxin , BoNT , and sold under the trade name Botox ) inhibits the release of acetylcholine at the neuromuscular junction by interfering with SNARE proteins . This toxin crosses into the nerve terminal through the process of endocytosis and subsequently interferes with SNARE proteins , which are necessary for ACh release . By doing so , it induces a transient flaccid paralysis and chemical denervation localized to the striated muscle that it has affected . The inhibition of the ACh release does not set in until approximately two weeks after the injection is made . Three months after the inhibition occurs , neuronal activity begins to regain partial function , and six months , complete neuronal function is regained . </P> <H3> Tetanus toxin ( edit ) </H3> <P> Tetanus toxin , also known as tetanospasmin is a potent neurotoxin produced by Clostridium tetani and causes the disease state , tetanus . The LD of this toxin has been measured to be approximately 1 ng / kg , making it second only to Botulinum toxin D as the deadliest toxin in the world . It functions very similarly to botunlinum neurotoxin ( BoNT ) by attaching and endocytosing into the presynaptic nerve terminal and interfering with SNARE protein complexes . It differs from BoNT in a few ways , most apparently in its end state , wherein tetanospasmin demonstrates a rigid / spastic paralysis as opposed to the flaccid paralysis demonstrated with BoNT . </P> <H3> Latrotoxin ( edit ) </H3> <P> Latrotoxin ( \u03b1 - Latrotoxin ) found in venom of widow spiders also affects the neuromuscular junction by causing the release of acetylcholine from the presynaptic cell . Mechanisms of action include binding to receptors on the presynaptic cell activating the IP3 / DAG pathway and release of calcium from intracellular stores and pore formation resulting in influx of calcium ions directly . Either mechanism causes increased calcium in presynaptic cell , which then leads to release of synaptic vesicles of acetylcholine . Latrotoxin causes pain , muscle contraction and if untreated potentially paralysis and death . </P> <H3> Snake venom ( edit ) </H3> <P> Snake venoms act as toxins at the neuromuscular junction and can induce weakness and paralysis . Venoms can act as both presynaptic and postsynaptic neurotoxins . </P> <P> Presynaptic neurotoxins , commonly known as \u03b2 - neurotoxins , affect the presynaptic regions of the neuromuscular junction . The majority of these neurotoxins act by inhibiting the release of neurotransmitters , such as acetylcholine , into the synapse between neurons . However , some of these toxins have also been known to enhance neurotransmitter release . Those that inhibit neurotransmitter release create a neuromuscular blockade that prevents signaling molecules from reaching their postsynaptic target receptors . In doing so , the victim of these snake bite suffer from profound weakness . Such neurotoxins do not respond well to anti-venoms . After one hour of inoculation of these toxins , including notexin and taipoxin , many of the affected nerve terminals show signs of irreversible physical damage , leaving them devoid of any synaptic vesicles . </P> <P> Postsynaptic neurotoxins , otherwise known as \u03b1 - neurotoxins , act oppositely to the presynaptic neurotoxins by binding to the postsynaptic acetylcholine receptors . This prevents interaction between the acetylcholine released by the presynaptic terminal and the receptors on the postsynaptic cell . In effect , the opening of sodium channels associated with these acetylcholine receptors is prohibited , resulting in a neuromuscular blockade , similar to the effects seen due to presynaptic neurotoxins . This causes paralysis in the muscles involved in the affected junctions . Unlike presynaptic neurotoxins , postsynaptic toxins are more easily affected by anti-venoms , which accelerate the dissociation of the toxin from the receptors , ultimately causing a reversal of paralysis . These neurotoxins experimentally and qualitatively aid in the study of acetylcholine receptor density and turnover , as well as in studies observing the direction of antibodies toward the affected acetylcholine receptors in patients diagnosed with myasthenia gravis . </P> <H2> Diseases ( edit ) </H2> Main article : Neuromuscular junction disease <P> Any disorder that compromises the synaptic transmission between a motor neuron and a muscle cell is categorized under the umbrella term of neuromuscular diseases . These disorders can be inherited or acquired and can vary in their severity and mortality . In general , most of these disorders tend to be caused by mutations or autoimmune disorders . Autoimmune disorders , in the case of neuromuscular diseases , tend to be humoral mediated , B cell mediated , and result in an antibody improperly created against a motor neuron or muscle fiber protein that interferes with synaptic transmission or signaling . </P> <H3> Autoimmune ( edit ) </H3> Myasthenia gravis ( edit ) <P> Myasthenia gravis is an autoimmune disorder where the body makes antibodies against either the acetylcholine receptor ( AchR ) ( in 80 % of cases ) , or against postsynaptic muscle - specific kinase ( MuSK ) ( 0 -- 10 % of cases ) . In seronegative myasthenia gravis low density lipoprotein receptor - related protein 4 is targeted by IgG1 , which acts as a competitive inhibitor of its ligand , preventing the ligand from binding its receptor . It is not known if seronegative myasthenia gravis will respond to standard therapies . </P> Neonatal MG ( edit ) <P> Neonatal MG is an autoimmune disorder that affects 1 in 8 children born to mothers who have been diagnosed with myasthenia gravis ( MG ) . MG can be transferred from the mother to the fetus by the movement of AChR antibodies through the placenta . Signs of this disease at birth include weakness , which responds to anticholinesterase medications , as well as fetal akinesia , or the lack of fetal movement . This form of the disease is transient , lasting for about three months . However , in some cases , neonatal MG can lead to other health effects , such as arthrogryposis and even fetal death . These conditions are thought to be initiated when maternal AChR antibodies are directed to the fetal AChR and can last until the 33rd week of gestation , when the \u03b3 subunit of AChR is replaced by the \u03b5 subunit . </P> Lambert - Eaton myasthenic syndrome ( edit ) <P> Lambert - Eaton myasthenic syndrome ( LEMS ) is an autoimmune disorder that affects the presynaptic portion of the neuromuscular junction . This rare disease can be marked by a unique triad of symptoms : proximal muscle weakness , autonomic dysfunction , and areflexia . Proximal muscle weakness is a product of pathogenic autoantibodies directed against P / Q - type voltage - gated calcium channels , which in turn leads to a reduction of acetylcholine release from motor nerve terminals on the presynaptic cell . Examples of autonomic dysfunction caused by LEMS include erectile dysfunction in men , constipation , and , most commonly , dry mouth . Less common dysfunctions include dry eyes and altered perspiration . Areflexia is a condition in which tendon reflexes are reduced and it may subside temporarily after a period of exercise . </P> <P> 50 -- 60 % of the patients that are diagnosed with LEMS also have present an associated tumor , which is typically small - cell lung carcinoma ( SCLC ) . This type of tumor also expresses voltage - gated calcium channels . Oftentimes , LEMS also occurs alongside myasthenia gravis . </P> <P> Treatment for LEMS consists of using 3 , 4 - diaminopyridine as a first measure , which serves to increase the compound muscle action potential as well as muscle strength by lengthening the time that voltage - gated calcium channels remain open after blocking voltage - gated potassium channels . In the US , treatment with 3 , 4 - diaminopyridine for eligible LEMS patients is available at no cost under an expanded access program . Further treatment includes the use of prednisone and azathioprine in the event that 3 , 4 - diaminopyridine does not aid in treatment . </P> Neuromyotonia ( edit ) <P> Neuromyotonia ( NMT ) , otherwise known as Isaac 's syndrome , is unlike many other diseases present at the neuromuscular junction . Rather than causing muscle weakness , NMT leads to the hyperexcitation of motor nerves . NMT causes this hyperexcitation by producing longer depolarizations by down - regulating voltage - gated potassium channels , which causes greater neurotransmitter release and repetitive firing . This increase in rate of firing leads to more active transmission and as a result , greater muscular activity in the affected individual . NMT is also believed to be of autoimmune origin due to its associations with autoimmune symptoms in the individual affected . </P> <H3> Genetic ( edit ) </H3> Congenital myasthenic syndromes ( edit ) <P> Congenital myasthenic syndromes ( CMS ) are very similar to both MG and LEMS in their functions , but the primary difference between CMS and those diseases is that CMS is of genetic origins . Specifically , these syndromes are diseases incurred due to mutations , typically recessive , in 1 of at least 10 genes that affect presynaptic , synaptic , and postsynaptic proteins in the neuromuscular junction . Such mutations usually arise in the \u03b5 - subunit of AChR , thereby affecting the kinetics and expression of the receptor itself . Single nucleotide substitutions or deletions may cause loss of function in the subunit . Other mutations , such as those affecting acetylcholinesterase and acetyltransferase , can also cause the expression of CMS , with the latter being associated specifically with episodic apnea . These syndromes can present themselves at different times within the life of an individual . They may arise during the fetal phase , causing fetal akinesia , or the perinatal period , during which certain conditions , such as arthrogryposis , ptosis , hypotonia , ophthalmoplegia , and feeding or breathing difficulties , may be observed . They could also activate during adolescence or adult years , causing the individual to develop slow - channel syndrome . </P> <P> Treatment for particular subtypes of CMS ( postsynaptic fast - channel CMS ) is similar to treatment for other neuromuscular disorders . 3 , 4 - Diaminopyridine , the first - line treatment for LEMS , is under development as an orphan drug for CMS in the US , and available to eligible patients under an expanded access program at no cost . </P> Bulbospinal muscular atrophy ( edit ) <P> Bulbospinal muscular atrophy , also known as Kennedy 's disease , is a rare recessive trinucleotide , polyglutamine disorder that is linked to the X chromosome . Because of its linkage to the X chromosome , it is typically transmitted through females . However , Kennedy 's disease is only present in adult males and the onset of the disease is typically later in life . This disease is specifically caused by the expansion of a CAG - tandem repeat in exon 1 found on the androgen - receptor ( AR ) gene on chromosome Xq 11 - 12 . Poly - Q - expanded AR accumulates in the nuclei of cells , where it begins to fragment . After fragmentation , degradation of the cell begins , leading to a loss of both motor neurons and dorsal root ganglia . </P> <P> Symptoms of Kennedy 's disease include weakness and wasting of the facial bulbar and extremity muscles , as well as sensory and endocrinological disturbances , such as gynecomastia and reduced fertility . Other symptoms include elevated testosterone and other sexual hormone levels , development of hyper - CK - emia , abnormal conduction through motor and sensory nerves , and neuropathic or in rare cases myopathic alterations on biopsies of muscle cells . </P> Duchenne muscular dystrophy ( edit ) <P> Duchenne muscular dystrophy is an X-linked genetic disorder that results in the absence of the structural protein dystrophin at the neuromuscular junction . It affects 1 in 3,600 -- 6,000 males and frequently causes death by the age of 30 . The absence of dystrophin causes muscle degeneration , and patients present with the following symptoms : abnormal gait , hypertrophy in the calf muscles , and elevated creatine kinase . If left untreated , patients may suffer from respiratory distress , which can lead to death . </P> <H2> See also ( edit ) </H2> <Ul> <Li> Synapse </Li> <Li> Skeletal muscle </Li> <Li> Nicotinic acetylcholine receptor </Li> <Li> Neuroeffector junction </Li> </Ul> <H2> External links ( edit ) </H2> <Ul> <Li> Histology image : 21501lca -- Histology Learning System at Boston University </Li> </Ul> <H2> Further reading ( edit ) </H2> <Ul> <Li> Kandel , ER ; Schwartz JH ; Jessell TM . ( 2000 ) . Principles of Neural Science ( 4th ed . ) . New York : McGraw - Hill . ISBN 0 - 8385 - 7701 - 6 . </Li> <Li> Nicholls , J.G. ; A.R. Martin ; B.G. Wallace ; P.A. Fuchs ( 2001 ) . From Neuron to Brain ( 4th ed . ) . Sunderland , MA. : Sinauer Associates . ISBN 0 - 87893 - 439 - 1 . </Li> <Li> Engel , A.G. ( 2004 ) . Myology ( 3rd ed . ) . New York : McGraw Hill Professional . ISBN 0 - 07 - 137180 - X . </Li> </Ul> <H2> References ( edit ) </H2> <Ol> <Li> Jump up ^ Levitan , Irwin ; Kaczmarek , Leonard ( August 19 , 2015 ) . `` Intercellular communication '' . The Neuron : Cell and Molecular Biology ( 4th ed . ) . New York , NY : Oxford Univerty Press . pp. 153 -- 328 . ISBN 0199773890 . </Li> <Li> ^ Jump up to : Nicholls , John G. , ; A. Robert Martin ; Paul A. Fuchs ; David A. Brown ; Matthew E. Diamond ; David A. Weisblat ( 2012 ) . From Neuron to Brain ( 5th ed . ) . Sunderland : Sinauer Associates . CS1 maint : Multiple names : authors list ( link ) </Li> <Li> ^ Jump up to : Sine SM ( July 2012 ) . `` End - plate acetylcholine receptor : structure , mechanism , pharmacology , and disease '' . Physiol. Rev. 92 ( 3 ) : 1189 -- 234 . doi : 10.1152 / physrev. 00015.2011 . PMC 3489064 . PMID 22811427 . </Li> <Li> Jump up ^ miller 's anaesthesia , 7th edition . </Li> <Li> Jump up ^ Scuka M , Mozrzymas JW ( 1992 ) . `` Postsynaptic potentiation and desensitization at the vertebrate end - plate receptors '' . Prog . Neurobiol. 38 ( 1 ) : 19 -- 33 . doi : 10.1016 / 0301 - 0082 ( 92 ) 90033 - B. PMID 1736323 . </Li> <Li> Jump up ^ Valenzuela D , Stitt T , DiStefano P , Rojas E , Mattsson K , Compton D , Nu\u00f1ez L , Park J , Stark J , Gies D ( 1995 ) . `` Receptor tyrosine sinase specific for the skeletal muscle lineage : expression in embryonic muscle , at the neuromuscular junction , and after injury '' . Neuron. 15 ( 3 ) : 573 -- 84 . doi : 10.1016 / 0896 - 6273 ( 95 ) 90146 - 9 . PMID 7546737 . </Li> <Li> Jump up ^ Glass D , Bowen D , Stitt T , Radziejewski C , Bruno J , Ryan T , Gies D , Shah S , Mattsson K , Burden S , DiStefano P , Valenzuela D , DeChiara T , Yancopoulos G ( 1996 ) . `` Agrin acts via a MuSK receptor complex '' . Cell. 85 ( 4 ) : 513 -- 23 . doi : 10.1016 / S0092 - 8674 ( 00 ) 81252 - 0 . PMID 8653787 . </Li> <Li> Jump up ^ Witzemann V ( November 2006 ) . `` Development of the neuromuscular junction '' . Cell Tissue Res. 326 ( 2 ) : 263 -- 71 . doi : 10.1007 / s00441 - 006 - 0237 - x . PMID 16819627 . </Li> <Li> Jump up ^ Okada K , Inoue A , Okada M , Murata Y , Kakuta S , Jigami T , Kubo S , Shiraishi H , Eguchi K , Motomura M , Akiyama T , Iwakura Y , Higuchi O , Yamanashi Y ( 2006 ) . `` The muscle protein Dok - 7 is essential for neuromuscular synaptogenesis '' . Science . 312 ( 5781 ) : 1802 -- 5 . doi : 10.1126 / science. 1127142 . PMID 16794080 . </Li> <Li> Jump up ^ Steinbeck , JA ; Jaiswal , MK ; Calder , EL ; Kishinevsky , S ; Weishaupt , A ; Toyka , KV ; Goldstein , PA ; Studer , L ( 7 January 2016 ) . `` Functional Connectivity under Optogenetic Control Allows Modeling of Human Neuromuscular Disease '' . Cell stem cell . 18 ( 1 ) : 134 -- 43 . doi : 10.1016 / j. stem. 2015.10. 002 . PMID 26549107 . </Li> <Li> Jump up ^ Papapetropoulos S , Singer C ( April 2007 ) . `` Botulinum toxin in movement disorders '' . Semin Neurol. 27 ( 2 ) : 183 -- 94 . doi : 10.1055 / s - 2007 - 971171 . PMID 17390263 . </Li> <Li> ^ Jump up to : Lewis RL , Gutmann L ( June 2004 ) . `` Snake venoms and the neuromuscular junction '' . Semin Neurol. 24 ( 2 ) : 175 -- 9 . doi : 10.1055 / s - 2004 - 830904 . PMID 15257514 . </Li> <Li> Jump up ^ Finsterer J , Papi\u0107 L , Auer - Grumbach M ( October 2011 ) . `` Motor neuron , nerve , and neuromuscular junction disease '' . Curr . Opin . Neurol. 24 ( 5 ) : 469 -- 74 . doi : 10.1097 / WCO. 0b013e32834a9448 . PMID 21825986 . CS1 maint : Multiple names : authors list ( link ) </Li> <Li> ^ Jump up to : Newsom - Davis J ( July 2007 ) . `` The emerging diversity of neuromuscular junction disorders '' . Acta Myol. 26 ( 1 ) : 5 -- 10 . PMC 2949330 . PMID 17915563 . </Li> <Li> ^ Jump up to : Luigetti M , Modoni A , Lo Monaco M ( October 2012 ) . `` Low rate repetitive nerve stimulation in Lambert - Eaton myasthenic syndrome : Peculiar characteristics of decremental pattern from a single - centre experience '' . Clin Neurophysiol. 124 ( 4 ) : 825 -- 6 . doi : 10.1016 / j. clinph. 2012.08. 026 . PMID 23036181 . </Li> <Li> ^ Jump up to : Titulaer MJ , Lang B , Verschuuren JJ ( December 2011 ) . `` Lambert - Eaton myasthenic syndrome : from clinical characteristics to therapeutic strategies '' . Lancet Neurol. 10 ( 12 ) : 1098 -- 107 . doi : 10.1016 / S1474 - 4422 ( 11 ) 70245 - 9 . PMID 22094130 . </Li> <Li> ^ Jump up to : ( 1 ) , Muscular Dystrophy Association Press Release </Li> <Li> ^ Jump up to : ( 2 ) , Rare Disease Report </Li> <Li> Jump up ^ Harper CM ( March 2004 ) . `` Congenital myasthenic syndromes '' . Semin Neurol. 24 ( 1 ) : 111 -- 23 . doi : 10.1055 / s - 2004 - 829592 . PMID 15229798 . </Li> <Li> Jump up ^ Engel AG , et al. ( April 2015 ) . `` Congenital myasthenic syndromes : pathogenesis , diagnosis , and treatment '' . Lancet Neurol. 14 ( 4 ) : 420 -- 34 . doi : 10.1016 / S1474 - 4422 ( 14 ) 70201 - 7 . PMC 4520251 . PMID 25792100 . </Li> <Li> Jump up ^ Engel AG , et al. `` New horizons for congenital myasthenic syndromes '' . Ann NY Acad Sci. 1275 : 1275 : 54 -- 62 . doi : 10.1111 / j. 1749 - 6632.2012. 06803. x . PMC 3546605 . PMID 23278578 . </Li> <Li> Jump up ^ ( 3 ) , FDA orphan drug designation </Li> <Li> ^ Jump up to : Finsterer J ( November 2010 ) . `` Perspectives of Kennedy 's disease '' . J. Neurol . Sci. 298 ( 1 -- 2 ) : 1 -- 10 . doi : 10.1016 / j. jns. 2010.08. 025 . PMID 20846673 . </Li> <Li> Jump up ^ Beyt\u00eda Mde L , Vry J , Kirschner J ( May 2012 ) . `` Drug treatment of Duchenne muscular dystrophy : available evidence and perspectives '' . Acta Myol. 31 ( 1 ) : 4 -- 8 . PMC 3440798 . PMID 22655510 . </Li> </Ol> <Table> <Tr> <Th_colspan=\"2\"> <Ul> <Li> </Li> <Li> </Li> <Li> </Li> </Ul> Nervous tissue </Th> </Tr> <Tr> <Th> CNS </Th> <Td> <Table> <Tr> <Th> Tissue Types </Th> <Td> <Ul> <Li> Grey matter </Li> <Li> White matter <Ul> <Li> Projection fibers </Li> <Li> Association fiber </Li> <Li> Commissural fiber </Li> <Li> Lemniscus </Li> <Li> Funiculus </Li> <Li> Fasciculus </Li> <Li> Nerve tract </Li> <Li> Decussation </Li> <Li> Commissure </Li> </Ul> </Li> <Li> Neuropil </Li> <Li> Meninges </Li> </Ul> </Td> </Tr> <Tr> <Th> Cell Types </Th> <Td> <Table> <Tr> <Th> Neuronal </Th> <Td> <Ul> <Li> Pyramidal </Li> <Li> Purkinje </Li> <Li> Granule </Li> </Ul> </Td> </Tr> <Tr> <Th> Glial </Th> <Td> <Table> <Tr> <Th> insulating : </Th> <Td> <Ul> <Li> Myelination : Oligodendrocyte </Li> </Ul> </Td> </Tr> <Tr> <Th> other </Th> <Td> <Ul> <Li> Astrocyte <Ul> <Li> Radial glial cell </Li> </Ul> </Li> <Li> Ependymal cells <Ul> <Li> Tanycyte </Li> </Ul> </Li> <Li> Microglia </Li> </Ul> </Td> </Tr> </Table> </Td> </Tr> </Table> </Td> </Tr> </Table> </Td> </Tr> <Tr> <Th> PNS </Th> <Td> <Table> <Tr> <Th> General </Th> <Td> <Ul> <Li> Dorsal <Ul> <Li> Root </Li> <Li> Ganglion </Li> <Li> Ramus </Li> </Ul> </Li> <Li> Ventral <Ul> <Li> Root </Li> <Li> Ramus </Li> </Ul> </Li> <Li> Ramus communicans <Ul> <Li> Gray </Li> <Li> White </Li> </Ul> </Li> <Li> Autonomic ganglion ( Preganglionic nerve fibers </Li> <Li> Postganglionic nerve fibers ) </Li> </Ul> </Td> </Tr> <Tr> <Th> Connective tissues </Th> <Td> <Ul> <Li> Epineurium </Li> <Li> Perineurium </Li> <Li> Endoneurium </Li> <Li> Nerve fascicle </Li> </Ul> </Td> </Tr> <Tr> <Th> Neuroglia </Th> <Td> <Ul> <Li> Myelination : Schwann cell <Ul> <Li> Neurolemma </Li> <Li> Myelin incisure </Li> <Li> Node of Ranvier </Li> <Li> Internodal segment </Li> </Ul> </Li> <Li> Satellite glial cell </Li> </Ul> </Td> </Tr> </Table> </Td> </Tr> <Tr> <Th> Neurons / nerve fibers </Th> <Td> <Table> <Tr> <Th> Parts </Th> <Td> <Table> <Tr> <Th> Soma </Th> <Td> <Ul> <Li> Axon hillock </Li> </Ul> </Td> </Tr> <Tr> <Th> Axon </Th> <Td> <Ul> <Li> Telodendron </Li> <Li> Axon terminals </Li> <Li> Axoplasm </Li> <Li> Axolemma </Li> <Li> Neurofibril / neurofilament </Li> </Ul> </Td> </Tr> <Tr> <Th> Dendrite </Th> <Td> <Ul> <Li> <Ul> <Li> Nissl body </Li> <Li> Dendritic spine </Li> <Li> Apical dendrite / Basal dendrite </Li> </Ul> </Li> </Ul> </Td> </Tr> </Table> </Td> </Tr> <Tr> <Th> Types </Th> <Td> <Ul> <Li> Bipolar </Li> <Li> Unipolar </Li> <Li> Pseudounipolar </Li> <Li> Multipolar </Li> <Li> Interneuron <Ul> <Li> Renshaw </Li> </Ul> </Li> </Ul> </Td> </Tr> <Tr> <Th> Afferent nerve fiber / Sensory neuron </Th> <Td> <Ul> <Li> GSA </Li> <Li> GVA </Li> <Li> SSA </Li> <Li> SVA </Li> <Li> fibers <Ul> <Li> Ia or A\u03b1 </Li> <Li> Ib or Golgi or A\u03b1 </Li> <Li> II or A\u03b2 and A\u03b3 </Li> <Li> III or A\u03b4 or fast pain </Li> <Li> IV or C or slow pain </Li> </Ul> </Li> </Ul> </Td> </Tr> <Tr> <Th> Efferent nerve fiber / Motor neuron </Th> <Td> <Ul> <Li> GSE </Li> <Li> GVE </Li> <Li> SVE </Li> <Li> Upper motor neuron </Li> <Li> Lower motor neuron <Ul> <Li> \u03b1 motorneuron </Li> <Li> \u03b2 motorneuron </Li> <Li> \u03b3 motorneuron </Li> </Ul> </Li> </Ul> </Td> </Tr> </Table> </Td> </Tr> <Tr> <Th> Termination </Th> <Td> <Table> <Tr> <Th> Synapse </Th> <Td> <Ul> <Li> Electrical synapse / Gap junction </Li> <Li> Chemical synapse <Ul> <Li> Synaptic vesicle </Li> <Li> Active zone </Li> <Li> Postsynaptic density </Li> </Ul> </Li> <Li> Autapse </Li> <Li> Ribbon synapse </Li> <Li> Neuromuscular junction </Li> </Ul> </Td> </Tr> <Tr> <Th> Sensory receptors </Th> <Td> <Ul> <Li> Meissner 's corpuscle </Li> <Li> Merkel nerve ending </Li> <Li> Pacinian corpuscle </Li> <Li> Ruffini ending </Li> <Li> Muscle spindle </Li> <Li> Free nerve ending </Li> <Li> Nociceptor </Li> <Li> Olfactory receptor neuron </Li> <Li> Photoreceptor cell </Li> <Li> Hair cell </Li> <Li> Taste bud </Li> </Ul> </Td> </Tr> </Table> </Td> </Tr> </Table> <Table> <Tr> <Th_colspan=\"2\"> <Ul> <Li> </Li> <Li> </Li> <Li> </Li> </Ul> Muscle tissue </Th> </Tr> <Tr> <Th> Smooth muscle </Th> <Td> <Ul> <Li> Calmodulin </Li> <Li> Vascular smooth muscle </Li> </Ul> </Td> </Tr> <Tr> <Th> Striated muscle </Th> <Td> <Table> <Tr> <Th> Skeletal muscle </Th> <Td> <Table> <Tr> <Th> Costamere / DAPC </Th> <Td> <Table> <Tr> <Th> Membrane / extracellular </Th> <Td> <Table> <Tr> <Th> DAP : </Th> <Td> <Ul> <Li> Sarcoglycan <Ul> <Li> SGCA </Li> <Li> SGCB </Li> <Li> SGCD </Li> <Li> SGCE </Li> <Li> SGCG </Li> <Li> SGCZ </Li> </Ul> </Li> <Li> Dystroglycan </Li> </Ul> </Td> </Tr> <Tr> <Td_colspan=\"2\"> <Ul> <Li> Sarcospan </Li> <Li> Laminin , alpha 2 </Li> </Ul> </Td> </Tr> </Table> </Td> </Tr> <Tr> <Th> Intracellular </Th> <Td> <Table> <Tr> <Td_colspan=\"2\"> <Ul> <Li> Dystrophin </Li> <Li> Dystrobrevin <Ul> <Li> </Li> <Li> </Li> </Ul> </Li> <Li> Syntrophin <Ul> <Li> </Li> <Li> B1 </Li> <Li> B2 </Li> <Li> G1 </Li> <Li> G2 </Li> </Ul> </Li> <Li> Syncoilin </Li> <Li> Dysbindin </Li> <Li> Synemin / desmuslin </Li> </Ul> </Td> </Tr> <Tr> <Th> related : </Th> <Td> <Ul> <Li> NOS1 </Li> <Li> Caveolin 3 </Li> </Ul> </Td> </Tr> </Table> </Td> </Tr> </Table> </Td> </Tr> <Tr> <Th> Sarcomere / ( a , i , and h bands ; z and m lines ) </Th> <Td> <Ul> <Li> Myofilament <Ul> <Li> thin filament / actin </Li> <Li> thick filament / myosin </Li> <Li> elastic filament / titin </Li> <Li> nebulin </Li> </Ul> </Li> </Ul> <Ul> <Li> Tropomyosin </Li> </Ul> <Ul> <Li> Troponin <Ul> <Li> </Li> <Li> </Li> <Li> </Li> </Ul> </Li> </Ul> </Td> </Tr> <Tr> <Th> Connective tissue </Th> <Td> <Ul> <Li> Epimysium </Li> <Li> Fascicle </Li> <Li> Perimysium </Li> <Li> Endomysium </Li> <Li> Connective tissue in skeletal muscle </Li> </Ul> </Td> </Tr> <Tr> <Th> General </Th> <Td> <Ul> <Li> Neuromuscular junction </Li> <Li> Motor unit </Li> <Li> Muscle spindle </Li> <Li> Excitation -- contraction coupling </Li> <Li> Sliding filament mechanism </Li> </Ul> </Td> </Tr> </Table> </Td> </Tr> <Tr> <Th> Cardiac muscle </Th> <Td> <Ul> <Li> Myocardium </Li> <Li> Intercalated disc </Li> <Li> Nebulette </Li> </Ul> </Td> </Tr> <Tr> <Th> Both </Th> <Td> <Table> <Tr> <Th> Fiber </Th> <Td> <Ul> <Li> Muscle fiber <Ul> <Li> intrafusal </Li> <Li> extrafusal </Li> </Ul> </Li> <Li> Myofibril </Li> <Li> Microfilament / Myofilament </Li> <Li> Sarcomere </Li> </Ul> </Td> </Tr> <Tr> <Th> Cells </Th> <Td> <Ul> <Li> Myoblast / Myocyte </Li> <Li> Myosatellite cell </Li> </Ul> </Td> </Tr> <Tr> <Th> Other </Th> <Td> <Ul> <Li> Desmin </Li> <Li> Sarcoplasm </Li> <Li> Sarcolemma <Ul> <Li> T - tubule </Li> </Ul> </Li> <Li> Sarcoplasmic reticulum </Li> </Ul> </Td> </Tr> </Table> </Td> </Tr> <Tr> <Th> Other / ungrouped </Th> <Td> <Ul> <Li> Myotilin </Li> <Li> Telethonin </Li> <Li> Dysferlin </Li> <Li> Fukutin </Li> <Li> Fukutin - related protein </Li> </Ul> </Td> </Tr> </Table> </Td> </Tr> </Table> <Ul> <Li> Biology portal </Li> <Li> Medicine portal </Li> </Ul> Retrieved from `` https://REMOVED_SECRET/w/index.php?title=Neuromuscular_junction&oldid=825334810 '' Categories : <Ul> <Li> Somatic motor system </Li> <Li> Skeletal muscle </Li> <Li> Neurophysiology </Li> </Ul> Hidden categories : <Ul> <Li> CS1 maint : Multiple names : authors list </Li> </Ul> <H2> </H2> <H3> </H3> <Ul> <Li> </Li> <Li> Talk </Li> <Li> </Li> <Li> </Li> <Li> </Li> </Ul> <H3> </H3> <Ul> <Li> </Li> <Li> </Li> </Ul> <H3> </H3> <Ul> </Ul> <H3> </H3> <Ul> <Li> </Li> <Li> </Li> <Li> </Li> </Ul> <H3> </H3> <Ul> </Ul> <H3> </H3> <H3> </H3> <Ul> <Li> </Li> <Li> Contents </Li> <Li> </Li> <Li> </Li> <Li> </Li> <Li> </Li> <Li> </Li> </Ul> <H3> </H3> <Ul> <Li> </Li> <Li> About Wikipedia </Li> <Li> </Li> <Li> </Li> <Li> </Li> </Ul> <H3> </H3> <Ul> <Li> </Li> <Li> </Li> <Li> </Li> <Li> </Li> <Li> </Li> <Li> </Li> <Li> </Li> <Li> </Li> </Ul> <H3> </H3> <Ul> <Li> </Li> <Li> </Li> <Li> </Li> </Ul> <H3> </H3> <Ul> <Li> </Li> </Ul> <H3> </H3> <Ul> <Li> </Li> <Li> Bosanski </Li> <Li> Catal\u00e0 </Li> <Li> \u010ce\u0161tina </Li> <Li> Deutsch </Li> <Li> Espa\u00f1ol </Li> <Li> \u0641\u0627\u0631\u0633\u06cc </Li> <Li> Fran\u00e7ais </Li> <Li> Italiano </Li> <Li> \u05e2\u05d1\u05e8\u05d9\u05ea </Li> <Li> Magyar </Li> <Li> Nederlands </Li> <Li> Polski </Li> <Li> Portugu\u00eas </Li> <Li> \u0420\u0443\u0441\u0441\u043a\u0438\u0439 </Li> <Li> Sloven\u010dina </Li> <Li> Sloven\u0161\u010dina </Li> <Li> \u0421\u0440\u043f\u0441\u043a\u0438 / srpski </Li> <Li> Suomi </Li> <Li> Svenska </Li> <Li> \u4e2d\u6587 </Li> </Ul> Edit links <Ul> <Li> This page was last edited on 12 February 2018 , at 20 : 32 . </Li> <Li> Text is available under the Creative Commons Attribution - ShareAlike License ; additional terms may apply . By using this site , you agree to the Terms of Use and Privacy Policy . Wikipedia \u00ae is a registered trademark of the Wikimedia Foundation , Inc. , a non-profit organization . </Li> </Ul> <Ul> <Li> </Li> <Li> About Wikipedia </Li> <Li> </Li> <Li> </Li> <Li> </Li> <Li> </Li> <Li> </Li> <Li> </Li> </Ul> <Ul> <Li> </Li> <Li> </Li> </Ul>", "long_answer_candidates": [{"start_token": 215, "top_level": true, "end_token": 369}, {"start_token": 216, "top_level": false, "end_token": 222}, {"start_token": 222, "top_level": false, "end_token": 277}, {"start_token": 277, "top_level": false, "end_token": 309}, {"start_token": 286, "top_level": false, "end_token": 307}, {"start_token": 298, "top_level": false, "end_token": 303}, {"start_token": 309, "top_level": false, "end_token": 314}, {"start_token": 314, "top_level": false, "end_token": 319}, {"start_token": 319, "top_level": false, "end_token": 331}, {"start_token": 331, "top_level": false, "end_token": 339}, {"start_token": 339, "top_level": false, "end_token": 349}, {"start_token": 349, "top_level": false, "end_token": 357}, {"start_token": 357, "top_level": false, "end_token": 368}, {"start_token": 369, "top_level": true, "end_token": 421}, {"start_token": 421, "top_level": true, "end_token": 593}, {"start_token": 593, "top_level": true, "end_token": 649}, {"start_token": 820, "top_level": true, "end_token": 1064}, {"start_token": 1072, "top_level": true, "end_token": 1218}, {"start_token": 1225, "top_level": true, "end_token": 1244}, {"start_token": 1226, "top_level": false, "end_token": 1232}, {"start_token": 1235, "top_level": false, "end_token": 1243}, {"start_token": 1269, "top_level": true, "end_token": 1442}, {"start_token": 1442, "top_level": true, "end_token": 1578}, {"start_token": 1584, "top_level": true, "end_token": 1748}, {"start_token": 1748, "top_level": true, "end_token": 1800}, {"start_token": 1800, "top_level": true, "end_token": 1867}, {"start_token": 1874, "top_level": true, "end_token": 2080}, {"start_token": 2080, "top_level": true, "end_token": 2158}, {"start_token": 2176, "top_level": true, "end_token": 2186}, {"start_token": 2193, "top_level": true, "end_token": 2321}, {"start_token": 2328, "top_level": true, "end_token": 2445}, {"start_token": 2451, "top_level": true, "end_token": 2550}, {"start_token": 2557, "top_level": true, "end_token": 2585}, {"start_token": 2585, "top_level": true, "end_token": 2723}, {"start_token": 2723, "top_level": true, "end_token": 2881}, {"start_token": 2893, "top_level": true, "end_token": 2996}, {"start_token": 3007, "top_level": true, "end_token": 3104}, {"start_token": 3109, "top_level": true, "end_token": 3262}, {"start_token": 3270, "top_level": true, "end_token": 3412}, {"start_token": 3412, "top_level": true, "end_token": 3466}, {"start_token": 3466, "top_level": true, "end_token": 3568}, {"start_token": 3572, "top_level": true, "end_token": 3684}, {"start_token": 3696, "top_level": true, "end_token": 3911}, {"start_token": 3911, "top_level": true, "end_token": 3976}, {"start_token": 3982, "top_level": true, "end_token": 4125}, {"start_token": 4125, "top_level": true, "end_token": 4200}, {"start_token": 4206, "top_level": true, "end_token": 4296}], "question_text": "what affect does acetylcholine have on the sarcolemma", "annotations": [{"yes_no_answer": "NONE", "long_answer": {"start_token": 421, "candidate_index": 14, "end_token": 593}, "short_answers": [{"start_token": 576, "end_token": 591}], "annotation_id": 5362118192820698977}], "document_url": "https://REMOVED_SECRET//w/index.php?title=Neuromuscular_junction&amp;oldid=825334810", "example_id": -8893375982061384676}